In conclusion, our study suggests that the combination of sotorasib and the next-generation WEE1 inhibitor ZN-c3 is a promising treatment for KRAS-G12C-mutated lung cancer with TP53 mutations. This evidence concerns the gene TP53 and lung cancer.